Holistic cancer genome profiling for every patient.

Swiss Med Wkly

MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, UK / Academic Laboratory of Medical Genetics, Addenbrookes Treatment Centre, Cambridge, UK.

Published: January 2020

Technological advances in the ability to read the human genome have accelerated the speed of sequencing, such that today we can perform whole genome sequencing (WGS) in one day. Until recently, genomic studies have largely been limited to seeking novel scientific discoveries. The application of new insights gained through cancer WGS into the clinical domain, have been relatively limited. Looking ahead, a vast amount of data can be generated by genomic studies. Of note, excellent organisation of genomic and clinical data permits the application of machine-learning methods which can lead to the development of clinical algorithms that could assist future clinicians and genomicists in the analysis and interpretation of individual cancer genomes. Here, we describe what can be gleaned from holistic whole cancer genome profiling and argue that we must build the infrastructure and educational frameworks to support the modern clinical genomicist to prepare for a future where WGS will be the norm.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043936PMC
http://dx.doi.org/10.4414/smw.2020.20158DOI Listing

Publication Analysis

Top Keywords

holistic cancer
8
cancer genome
8
genome profiling
8
genomic studies
8
genome
4
profiling patient
4
patient technological
4
technological advances
4
advances ability
4
ability read
4

Similar Publications

Platinum drugs upregulate CXCR4 and PD-L1 expression via ROS-dependent pathways, with implications for novel combined treatment in gastric cancer.

J Pathol Clin Res

January 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, PR China.

CXC chemokine receptor 4 (CXCR4) and programmed cell death-ligand 1 (PD-L1) are two critical molecules involved in the tumor immune microenvironment. However, the impact of platinum drugs, such as cisplatin, on CXCR4 or PD-L1 expression and the underlying mechanisms in gastric cancer (GC) remain unknown. Moreover, the correlation between their expression levels in GC remains elusive.

View Article and Find Full Text PDF

Factors associated with eye disorders and diseases: A retrospective study.

Pak J Med Sci

January 2025

Olgun Goktas, Associate Professor, Uludag University Family Health Center, Nilufer, Bursa, Turkey.

Objective: To retrospectively identify the factors associated with eye disorders and diseases.

Methods: The retrospective study was carried out in Bursa Uludag University Family Health Center in Turkey between 1-30 September 2023. The data of individuals who were registered with the Family Health Center and whose eye disorders and diseases were known were evaluated retrospectively.

View Article and Find Full Text PDF

Analysis of Risk Factors for Gastric Cancer and Precancerous Lesions: A Case-Control Study.

J Dig Dis

January 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi Province, China.

Objectives: To investigate the correlation between gastric xanthoma (GX) and precancerous lesions (PCL) and gastric cancer (GC), and to explore other potential risk factors for PCL and GC in northwest China.

Methods: A case-control study was conducted from September 2022 to September 2023 at Xijing Hospital, Air Force Medical University (Xi'an, Shaanxi Province, China). The patients who underwent gastroscopy were enrolled and divided into the chronic gastritis (CG) group (n = 423), PCL group (n = 422), and GC group (n = 415).

View Article and Find Full Text PDF

Background: Disease-focus management of late-stage cancer without addressing patients' preferences or quality of life (QoL) can lead to unsatisfactory patient and disease outcomes.

Methods: A PRISMA-adherent systematic review of the literature was conducted via PubMed, Embase, Scopus, and Google Scholar to assess the current late-stage cancer treatment modality, setting, timing, and cost, their impact on patient and disease outcomes, and possible interventions for improvement.

Results: Out of many studies, twelve from North America, Western Europe, and Asia met our inclusion criteria.

View Article and Find Full Text PDF

Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value.

Sci Rep

January 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Pathology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, China.

Delta-like protein (DLL3) is a novel therapeutic target. DLL3 expression in gastroenteropancreatic neuroendocrine tumors (GEP-NECs) is poorly understood, complicating the distinction between well-differentiated neuroendocrine tumors G3 (NET G3) and poorly differentiated NEC. DLL3 immunohistochemistry (IHC) was performed on 248 primary GEP-NECs, correlating with clinicopathological parameters, NE markers, PD-L1, Ki67 index, and prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!